CTOs on the Move

xbiotech usa inc

www.xbiotech.com

 
xbiotech usa inc is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Curie Co

Curie Co is replacing chemicals with clean, sustainable proteins and enzymes.

Kurion

Kurion creates technological solutions to minimize and stabilize nuclear and hazardous waste for safe, secure and permanent disposal.  Kurion’s suite of waste separation, stabilization and robotic technologies are complemented by engineering and environmental services that together provide an execution platform to service the world’s largest nuclear and hazardous waste sites. Backed by venture capital firms Lux Capital, Firelake Capital and Acadia Woods Partners, the Kurion executive team employs a collective 150 years of industry experience managing nuclear and hazardous waste for commercial and government sites worldwide. Kurion is based in Irvine, Calif., and operates a technology development center at its radioactive materials licensed facility in Oak Ridge, Tenn.; a detritiation testing facility in Houston, Texas; two facilities in Richland, Wash., for non-radioactive demonstration testing, engineering and storage of mobile systems; and an office in Loveland, Colo. for engineering design and development.

BioVir Laboratories

BioVir Laboratories is a Benicia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Silk Technologies

SILKTECH focuses on innovating and developing silk-derived protein (SDP) products for ophthalmic applications. The company`s patented SDP material is currently being developed as a novel compound for the treatment of patients with dry eye disease. SILKTECH is based in Plymouth, MN and is financially backed by a combination of angels, grants and recently from a financing round by Skyview Ventures LLC.

Entasis

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.